MedPath

Cobolimab

Generic Name
Cobolimab
Drug Type
Biotech
CAS Number
2022215-65-0
Unique Ingredient Identifier
3K5H4TX2KP
Background

Cobolimab is under investigation in clinical trial NCT04655976 (Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants).

Clinical Trials
Related News

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

Phase 1
Recruiting
Conditions
Ependymoma
Osteosarcoma
Melanoma
Hodgkin Lymphoma
High and Low Grade Glioma
Glioblastoma Multiforme (GBM)
Diffuse Intrinsic Pontine Glioma (DIPG)
Hepatic Tumors
Hepatocellular Carcinoma (HCC)
Hepatoblastoma
Interventions
First Posted Date
2024-07-26
Last Posted Date
2025-05-09
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
95
Registration Number
NCT06521567
Locations
πŸ‡ͺπŸ‡Έ

GSK Investigational Site, Valencia, Spain

Dostarlimab and Cobolimab in Advanced Cervical Cancer

Phase 2
Recruiting
Conditions
Cervical Cancer
Advanced Cervical Carcinoma
Metastatic Cervical Cancer
Metastatic Cervical Carcinoma
Recurrent Cervical Carcinoma
Interventions
First Posted Date
2024-02-02
Last Posted Date
2025-04-06
Lead Sponsor
Meghan Shea
Target Recruit Count
66
Registration Number
NCT06238635
Locations
πŸ‡ΊπŸ‡Έ

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

πŸ‡ΊπŸ‡Έ

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Phase 3
Active, not recruiting
Conditions
Lung Cancer, Non-Small Cell
Interventions
First Posted Date
2020-12-07
Last Posted Date
2024-11-05
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
758
Registration Number
NCT04655976
Locations
πŸ‡¬πŸ‡§

GSK Investigational Site, Manchester, United Kingdom

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Phase 1
Active, not recruiting
Conditions
Neoplasms
Interventions
First Posted Date
2020-06-24
Last Posted Date
2025-03-14
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
107
Registration Number
NCT04446351
Locations
πŸ‡°πŸ‡·

GSK Investigational Site, Seoul, Korea, Republic of

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Phase 1
Active, not recruiting
Conditions
Advanced Cancer
Non Small Cell Lung Cancer Stage IIIB
Neoplasms
Solid Tumor
Non Small Cell Lung Cancer Metastatic
Non Small Cell Lung Cancer
Metastatic Cancer
Interventions
Drug: Carboplatin-Paclitaxel
Drug: Carboplatin-Pemetrexed
Drug: Carboplatin-Nab-Paclitaxel
First Posted Date
2017-10-12
Last Posted Date
2024-05-29
Lead Sponsor
Tesaro, Inc.
Target Recruit Count
58
Registration Number
NCT03307785
Locations
πŸ‡ΊπŸ‡Έ

GSK Investigational Site, San Marcos, Texas, United States

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

First Posted Date
2016-06-29
Last Posted Date
2024-06-20
Lead Sponsor
Tesaro, Inc.
Target Recruit Count
447
Registration Number
NCT02817633
Locations
πŸ‡¨πŸ‡³

GSK Investigational Site, Tainan, Taiwan

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

First Posted Date
2016-03-31
Last Posted Date
2024-12-27
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
829
Registration Number
NCT02723955
Locations
πŸ‡ͺπŸ‡Έ

GSK Investigational Site, Sevilla, Spain

Β© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy